Quick Overview: Marshall R. Posner, MD, The Tisch Cancer Institute, New York, NY, describes an analysis of patients with locally advanced human ... Icro Meattini, MD, University of Florence, Florence, Italy, discusses Maria Vittoria Dieci, MD, PhD, University of Padova, Padova, Italy, discusses the evolving strategies in managing HER2-positive ...
De Escalating Chemo Radiotherapy In - Detailed Overview & Context
Marshall R. Posner, MD, The Tisch Cancer Institute, New York, NY, describes an analysis of patients with locally advanced human ... Icro Meattini, MD, University of Florence, Florence, Italy, discusses Maria Vittoria Dieci, MD, PhD, University of Padova, Padova, Italy, discusses the evolving strategies in managing HER2-positive ... ... MD, GasthuisZusters Antwerpen, Antwerp, Belgium, discusses the increasing importance of the Evandro De Azambuja, MD, PhD, Jules Bordet Institute, Brussels, Belgium, discusses Icro Meattini, MD, University of Florence, Florence, Italy, discusses the
There have been significant advances in pinpointing who can forgo Ari Rosenberg, MD, University of Chicago, Chicago, IL, talks on the rationale behind the Phase II E3311 (NCT01898494) study ... David Routman, MD, Mayo Clinic, Rochester, MN, discusses the rationale and study design of the MC1675 trial (NCT02908477) ... Icro Meattini, MD, University of Florence, Florence, Italy, comments on the current treatment strategies for patients after breast ... We are pleased to share updates to the GRACE Patient Education Program on HPV Advances. In this video, Dr. Wendell ... In this video series, Shahid S. Ahmed, MD, and Jordan Ciuro, MD, both of Emory Winship Cancer Institute, discuss the evolving ...
Judy Boughey, MD, Mayo Clinic Comprehensive Cancer Center, Rochester, MN, discusses Andrea Necchi, MD, IRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy, highlights the potential to Michiel Strijbos, MD, GasthuisZusters Antwerpen, Antwerp, Belgium, discusses the increased focus on David Routman, MD, Mayo Clinic, Rochester, MN, reports the results of the MC1675 trial (NCT02908477) that evaluated the use ... Patients with very small ER+ breast tumors have excellent outcomes, leading researchers to question whether
